Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ospedale Santa Croce-Carle Cuneo
• Collaborators: Consorzio Mario Negri Sud; GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)
• Treatments: Doxorubicin; Liposomal doxorubicin; Procarbazine; Vincristine

Criteria

Inclusion Criteria:

• Patients with advanced classical Hodgkin Lymphoma according to the World Health Organization classification

• Aged 18-60

• Not previously treated

• Stages IIB to IV B

• All IPS prognostic groups

• Patients who have signed an informed consent form

Exclusion Criteria:

• Patients aged more than 60.

• Concomitant or previously treated neoplastic disorder less than 5 year before the diagnosis of Hodgkin's lymphoma.

• Psychiatric disorders

• Uncontrolled infectious disease

• Impaired cardiac (EF < 50%) , renal (creatinine clearance < 60 ml/m)

• HIV, HBV DNA, HCV RNA positive markers

• Pregnancy and lactation

• Patients with uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl